Andere Sprachen Vericel Corporation

Aktien

A12FU4

US92346J1088

VCEL

Pharmazeutika

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.01.2025			% 5 Tage	% 1. Jan.
59.07 ^USD	+4.83%		-0.72%	+7.58%

15.01.	MÄRKTE USA/Fest - Wall Street von Banken-Zahlen und Preisdaten angetrieben	DJ
15.01.	MÄRKTE USA/Fest - Banken-Zahlen und Inflationsdaten treiben Börsen	DJ

Andere Sprachen

Vericel Reports Q4 Preliminary Unaudited Revenue -- Shares Fall	14.01.
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets	14.01.
Vericel Corporation Provides Financial Guidance for the Fourth Quarter and Year Ended December 31, 2024 and for the Full-Year 2025	14.01.
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025	08.01.
Vericel's Q3 Net Loss Narrows, Revenue Increases	07.11.
Vericel : Q3 2024 Earnings Presentation	07.11.
Earnings Flash (VCEL) VERICEL CORPORATION Posts Q3 Revenue $57.9M	07.11.
Vericel : Reports Third Quarter 2024 Financial Results Form 8 K	07.11.
Vericel Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	07.11.
Vericel Reports Third Quarter 2024 Financial Results	07.11.
Vericel Reports Third Quarter 2024 Financial Results	07.11.
Vericel Corporation Maintains Revenue Guidance for the Year 2024	07.11.
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024	24.10.24
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024	24.10.24
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024	29.08.24
Vericel Says US FDA Approves sBLA for Tissue Restoring Knee Repair Treatment - Shares Up Pre-Bell	26.08.24
Vericel Announces FDA Approval and Commercial Availability of MACI Arthro	26.08.24
Vericel Corporation Announces FDA Approval and Commercial Availability of MACI Arthro	26.08.24
Vericel Files Mixed Shelf	16.08.24
Vericel Gets US FDA Approval of NexoBrid to Treat Children With Severe Thermal Burns	15.08.24
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns	15.08.24
Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns	15.08.24
Vericel Corporation Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns	15.08.24
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024	07.08.24
Vericel's Q2 Net Loss Narrows, Revenue Increases; Shares Decline	01.08.24

Werden Sie Mitglied, um Zugang zu mehr Nachrichten zu erhalten.

100% kostenlose Registrierung

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vericel Corporation

Aktien

A12FU4

US92346J1088

VCEL

Pharmazeutika

Andere Sprachen

Filter